超声引导下聚桂醇硬化治疗肝囊肿患者疗效研究*

doi:10.3969/j.issn.1672-5069.2025.04.035

摘要/Abstract

摘要： 目的比较超声引导下聚桂醇或无水乙醇注射硬化治疗肝囊肿(HC)患者的疗效。方法 2022年3月～2024年3月河南省人民医院、郑州市中心医院和河南省儿童医院收治的91例HC患者,被随机分为对照组45例和观察组46例,分别在超声引导下给予无水乙醇或聚桂醇注射治疗。使用全自动免疫分析仪检测血清高尔基体蛋白73(GP73)、蛋白二硫化物异构酶 A3(PDIA3)和壳多糖酶3样蛋白1 ( CHI3L1),采用ELISA法检测血清超氧化物歧化酶(SOD)、核因子E2相关因子2(Nrf2)和血红素加氧酶-1(HO-1)。结果在治疗后,观察组血清ALT和AST水平分别为48.4±9.2U/L和38.4±7.3U/L,均显著低于对照组【分别为59.8±11.3U/L和62.0±14.3U/L,P<0.05】;观察组血清GP73、PDIA3和CHI3L1水平分别为24.4±3.6pg/L、67.7±5.2ng/mL和46.4±5.8ng/L,均显著低于对照组【分别为36.4±5.1pg/L、92.7±5.4ng/mL和65.8±6.4ng/L,P<0.05】; 观察组血清SOD、Nrf2和HO-1水平分别为83.5±8.3 U/L、713.3±82.3 U/L和27.7±3.1U/L,均显著高于对照组【分别为77.5±7.8U/L、664.7±75.3U/L和23.7±2.5U/L,P<0.05】;术后,观察组不良反应发生率为6.5%,显著低于对照组的24.4%(P<0.05);在治疗6个月后复查,观察组囊肿消失率为87.0%,显著高于对照组的66.7%(P<0.05)。结论本研究结果推荐在超声引导下注射聚桂醇硬化治疗HC患者,疗效较好。

关键词: 肝囊肿, 超声引导, 聚桂醇, 无水乙醇, 治疗

Abstract: Objective The aim of this study was to investigate ultrasound-guided polidocanol sclerotherapy in patients with hepatic cysts (HC). Methods Ninety-one patients with HC were recruited in Henan Provincial Children's Hospital between March 2022 and March 2024, and were randomly divided into control group (n=45) and observation group (n=46), receiving ethanol sclerotherapy, or polidocanol sclerotherapy under ultrasound-guidance. Serum Golgi protein 73 (GP73), protein disulfide isomerase A3 (PDIA3) and chitinase 3-like protein 1 (CHI3L1) levels were detected by using automatic immunoassay analyzer, and serum superoxide dismutase (SOD), nuclear factor E2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1) levels were measured by ELISA. Results After treatment, serum ALT and AST levels in the observation group were 48.4±9.2U/L and 38.4±7.3U/L, both significantly lower than [59.8±11.3U/L and 62.0±14.3U/L, P<0.05] in the control; serum GP73, PDIA3 and CHI3L1 levels were 24.4±3.6pg/L, 67.7±5.2ng/mL and 46.4±5.8ng/L, all much lower than [36.4±5.1pg/L, 92.7±5.4ng/mL and 65.8±6.4ng/L, respectively, P<0.05] in the control group; serum SOD, Nrf2 and HO-1 levels were 83.5±8.3 U/L, 713.3±82.3 U/L and 27.7±3.1U/L, all much higher than [77.5±7.8U/L, 664.7±75.3U/L and 23.7±2.5U/L, respectively, P<0.05] in the control; post-operationally, incidence of adverse effects in the observation group was 6.5%, much lower than 24.4%(P<0.05)in the control; six months after sclerotherapy, disappearance rate of HC in the observation group was 87.0%, much higher than 66.7%(P<0.05)in the control group. Conclusion Our observation backs up lauromacrogol sclerotherapy under ultrasound-guidance in patients with HC, which is efficacious and safe.

Key words: Hepatic cysts, Ultrasound-guidance, Polidocanol, Ethanol, Therapy

赵慧萍, 唐奇琼, 崔智飞. 超声引导下聚桂醇硬化治疗肝囊肿患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(4): 617-620.

Zhao Huiping, Tang Qiqiong, Cui Zhifei. Ultrasound-guided polidocanol sclerotherapy in patients with hepatic cysts[J]. Journal of Practical Hepatology, 2025, 28(4): 617-620.

参考文献

[1] Ji-De A, Chai J P, Jia S L, et al. Historical changes in surgical strategy and complication management for hepatic cystic echinococcosis. World J Gastrointest Surg, 2023, 15(8): 1591.
[2] Mihetiu A, Bratu D G, Sandu A, et al. Specialized laparoscopic devices in the treatment of hydatic hepatic cysts: a retrospective analysis and review of the literature. Cureus, 2024, 16(3):212-216.
[3] Trigui A, Khmekhem N, Fendri S, et al. Viability predictive factors of the daughter vesicles in hepatic cystic echinococcosis. BMC Infect Dis, 2024, 24(1): 43.
[4] Dai Y, Zhang X, Xu Y, et al. The protective effects of cinnamyl alcohol against hepatic steatosis, oxidative and inflammatory stress in nonalcoholic fatty liver disease induced by childhood obesity. Immunol Investig, 2023, 52(8): 1008-1022.
[5] Wang S, Yin M, Xia Z. Efficacy and preliminary dose studies of ultrasound-guidedsclerotherapy with lauromacrogol for the treatment of implanted hepatic tumors in rabbits. J Gastrointest Oncol, 2023, 14(1): 265.
[6] 张静,林铤,孙翔. 超声引导下穿刺抽液联合聚桂醇置换冲洗硬化治疗巨大肝囊肿患者疗效研究. 实用肝脏病杂志,2022,25(4):571-574.
[7] Marrero J A, Ahn J, Reddy R K, et al. ACG clinical guideline: the diagnosis and management of focal liver lesions. Am J Gastroenterol, 2014, 109(9): 1328-1347.
[8] Zhang Z Y, Wang Z M, Huang Y. Polycystic liver disease: classification, diagnosis, treatment process, and clinical management. World J Hepatol, 2020, 12(3): 72.
[9] Ugli N Z N, Servetovna A A, Ogli G S O, et al. Diagnosis and surgical treatment of echinococcal cyst of the liver. Res Focus, 2024, 3(4): 76-81.
[10] Masyuk T V, Masyuk A I, LaRusso N F. Polycystic liver disease: advances in understanding and treatment. Annu Rev Pathol Mech Dis, 2022, 17(1): 251-269.
[11] Khvorostov Y, Tsivenko O, Dushyk L, et al. Puncture methods of treatment of patients with fluid formations of the pancreas and liver. J VN Karazin Kharkiv Natl Univ, 2020 (39): 32-39.
[12] 李玮健,刘昕,舒红艳. 超声引导下聚桂醇与无水乙醇注射硬化治疗肝囊肿患者疗效比较研究. 实用肝脏病杂志,2024,27(3):450-453.
[13] 王苓入,苏虹,郝晓炜,等. 超声引导下PTGD联合聚桂醇硬化治疗单纯性肝囊肿患者疗效研究. 实用肝脏病杂志,2024,27(3):454-457.
[14] Shen R, Cheng R, Zhou H, et al. Ultrasonography-guided radiofrequency ablation combined with lauromacrogol sclerotherapy for mixed thyroid nodules. Am J Transl Res, 2021, 13(5): 5035.
[15] Zou L, Li C, Chen X, et al. The anti-inflammatory effects of cinnamyl alcohol on sepsis-induced mice via the NLRP3 inflammasome pathway. Ann Transl Med, 2022, 10(2):713-718.
[16] 张琼,陈士颖,夏维. 超声引导下无水乙醇与聚桂醇硬化治疗单纯性肝囊肿患者效果比较研究. 实用肝脏病杂志,2023,26(3):428-431.
[17] Jain P, Batta A K, Singh P. Comparative study of serum levels of gamma-glutamyl transferase,aspartate aminotransferase (AST), alanine transaminase (ALT), and bilirubin in patients with chronic hepatitis. Indian J Med Biochem, 2022, 26(3): 74.
[18] Peng Y, Zeng Q, Wan L, et al. GP73 is a TBC-domain Rab GTPase-activating protein contributing to the pathogenesis of non-alcoholic fatty liver disease without obesity. Nat Commun, 2021, 12(1): 7004.
[19] Lapatta U N Y F, Afifah D N, Pramono A, et al. Effect of dangke administration on serum TNF-a and liver SOD levels in rats induced by a high-fat, high-sugar diet. Aceh Nutr J, 2024, 9(4): 647-654.
[20] Alharbi K S, Almalki W H, Albratty M, et al. The therapeutic roleof nutraceuticals targeting the Nrf2/HO‐1 signaling pathway in liver cancer. J Food Biochem, 2022, 46(10): e14357.

超声引导下聚桂醇硬化治疗肝囊肿患者疗效研究^*

Ultrasound-guided polidocanol sclerotherapy in patients with hepatic cysts

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	呙冬慧, 陈婷, 茅明. 富马酸替诺福韦二吡呋酯联合当飞利肝宁胶囊治疗慢性乙型肝炎患者临床研究^*[J]. 实用肝脏病杂志, 2025, 28(4): 509-512.
[2]	樊予惠, 黄素培, 侯爱敏, 王世英. 索磷布韦联合达诺瑞韦治疗基因3型初治的慢性丙型肝炎患者疗效和安全性分析^*[J]. 实用肝脏病杂志, 2025, 28(4): 517-520.
[3]	林丽泉, 白晓苏, 张爱兰, 程小桂. 利托那韦增强的达诺瑞韦联合索磷布韦和利巴韦林方案治疗基因3型慢性丙型肝炎患者疗效和安全性研究^*[J]. 实用肝脏病杂志, 2025, 28(4): 521-524.
[4]	宋小宇, 陈宁, 高凤, 余仲苏. 儿童非嗜肝性病毒感染性肝损害患者病因与转归分析^*[J]. 实用肝脏病杂志, 2025, 28(4): 525-528.
[5]	高倩, 陈璇, 周轶群, 杨欣, 康秀丽. 五脂胶囊联合复方甘草酸苷治疗非酒精性脂肪性肝炎患者疗效临床研究^*[J]. 实用肝脏病杂志, 2025, 28(4): 529-532.
[6]	唐晓路, 邓玲, 王金春, 沈美龙. 水飞蓟素联合甘草酸二铵治疗非酒精性脂肪性肝炎患者疗效临床研究^*[J]. 实用肝脏病杂志, 2025, 28(4): 537-540.
[7]	王超智, 王珊, 田婉婷. 依折麦布联合多烯磷脂酰胆碱治疗非酒精性脂肪性肝炎患者疗效初步研究^*[J]. 实用肝脏病杂志, 2025, 28(4): 541-544.
[8]	张淑玮, 张惠娟, 周杰. 罗格列酮联合二甲双胍治疗非酒精性脂肪性肝病合并T2DM患者临床疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(4): 545-548.
[9]	李莉, 朱文娟, 郭妮, 张彤, 杨亚峰, 赵芯. 泼尼松龙联合异甘草酸镁治疗自身免疫性肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(4): 561-564.
[10]	李晓静, 黄丽, 莫波, 沈才飞. 影响泼尼松治疗自身免疫性肝炎患者完全应答的多因素分析^*[J]. 实用肝脏病杂志, 2025, 28(4): 565-568.
[11]	王燕燕, 周桐桐, 李娜, 卞兆连. PBC和PBC-AIH重叠综合征患者外周血树突状细胞及其亚群变化初步研究^*[J]. 实用肝脏病杂志, 2025, 28(4): 569-572.
[12]	彭志芳, 吴莉, 盛秀红. 熊去氧胆酸治疗原发性胆汁性胆管炎患者血清MMP-1和IL-6水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2025, 28(4): 573-576.
[13]	施海群, 钱杰, 沈国倩, 赵萌. 索磷布韦联合维帕他韦治疗丙型肝炎肝硬化患者临床疗效和门脉超声检查指标变化研究^*[J]. 实用肝脏病杂志, 2025, 28(4): 585-588.
[14]	彭贺, 郝建玲, 黄建业, 李楠楠, 骆锦前. TACE术联合靶向和免疫治疗原发性肝癌患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(4): 593-596.
[15]	张聪, 张涛, 张骞. 超声造影诊断肝血管瘤及其预判肝动脉栓塞治疗的效果研究^*[J]. 实用肝脏病杂志, 2025, 28(4): 601-604.